Rznomics, Non-linear RNA Structure Platform company, apply the Lipo-pam™ delivery from Cha Vaccine Institute

  

Rznomics announced on the 9th that it has signed an "agreement for joint development of next-generation vaccines" based on the next-generation RNA platform with Cha Vaccine Institute, an affiliate of Cha Biotech. Based on this agreement, Rznomics and Cha Vaccine Institute will jointly research and develop next-generation RNA vaccines, and will also cooperate for the exchange of physical and human resources necessary for the development process..

  

The RNA vaccine developed by the two companies this time is the next-generation technology of the mRNA vaccine currently used in the COVID-19 vaccine. The company explained that the next-generation RNA vaccine is based on a non-linear RNA structure and has the advantage of long-lasting efficacy due to its high stability compared to the linear mRNA vaccine.

 

The Cha Vaccine Institute first selects a target disease to be applied to the vaccine and designs an antigen accordingly. Rznomics is in charge of producing, optimizing, manufacturing, and processing RNA vaccines that express antigens designed by Cha Vaccine Institute based on its own nonlinear RNA structure platform. The Cha Vaccine Institute uses "Lipo-pam™" as a delivery material for RNA vaccines to non-clinically study vaccines and derive vaccine candidate substances.

  

The Cha Vaccine Institute has developed its own immune enhancers L-pampo™ and Lipo-pam™, which are necessary for the manufacture of recombinant protein vaccines. Based on this, clinical development of preventive and therapeutic vaccines for infectious diseases such as hepatitis B and shingles is underway, and pipelines are being expanded to anti-cancer vaccines and immuno-cancer drugs.

  

Rznomics is an RNA-based new drug developer. The core technology is developing therapies for anticancer drugs, degenerative diseases, and genetic diseases based on the mechanism of editing target RNA that causes diseases with trans-Ribozyme and replacing the cut part with other treatment RNA at the same time. It also has its own nonlinear RNA structure platform technology.

  

Jung-sun, Yeom, CEO of Cha Vaccine Institute, said, "As the two companies with their own unique technologies cooperate, the development of next-generation vaccine platforms and new pipelines using them will be smoother. Through this MOU, Cha Vaccine Institute will also expand its business area to new areas such as RNA vaccines.

 

"We expect this collaboration to accelerate the development of next-generation vaccines based on our new RNA structure technology," said Seong-wook, Lee, CEO of Rznomics. "We will prove the versatility, usability, and excellence of Rznomics’ unique RNA platform technology."